Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
Aspirin Yellow Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics

*on advice of clinical genetics

Patient weight <75kg: 150mg daily

Patient weight >75kg: 300mg daily

Asprin (UPDATED) Yellow Lynch syndrome cancer risk reduction

Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics

AZATHIOPRINE Orange Rheumatological disease

Full SCA

Bismuth, Metronidazole & Tetracycline ( Pylera) (NEW) Green Eradication of H. Pylori for patients with penicillin allergy already exposed to clarithromycin

Use in line with local antimicrobial guidelines.

Denosumab (Xgeva) Red Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min)
Estradiol & Medroxyprogesterone (Tridestra) (NEW) Green Hormone replacement therapy
Estradiol & Norethisterone (Trisequens) (NEW) Green Hormone replacement therapy
ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) (UPDATED) Yellow For treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

Treatment for 6-12 months at the direction of specialist team. In line with NICE TA832

classification or pathway

Finerenone Green Stage 3 and 4 chronic kidney disease associated with diabetes

For treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults in line with NICE TA877. Use in line with the CKD Pathway.

Lebrikizumab (NEW) Red For treating moderate to severe atopic dermatitis in people 12 years and over

TA986

LEFLUNOMIDE (UPDATED) Orange Rheumatological disease

Full SCA     Request form

METHOTREXATE Oral (UPDATED) Orange Rheumatological disease

 Full SCA            Request form

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied.

Nephrotrans (UPDATED) Yellow metabolic acidosis in chronic kidney disease

Treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment only (limited use as a 2nd line option for patients who cannot tolerate the standard capsules e.g. due to bloating).’ To be initiated by renal team only.

PENICILLAMINE Orange Rheumatoid arthritis

Full SCA

SULFASALAZINE Orange Rheumatological disease

Full SCA

Tenecteplase (NEW) Red For treating acute ischaemic stroke

TA990

Trihexyphenidyl Green Parkinson, Drug-induced extrapyramidal symptoms, Dystonia
Varenicline Tartrate (Champix) Grey Smoking cessation in adults

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more